JANX · CIK 0001817713 · operating
Janux Therapeutics is a clinical-stage biopharmaceutical company developing immunotherapies for cancer treatment. The company's proprietary platforms—Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr)—are designed to activate immune responses specifically in the tumor microenvironment. Two candidates are currently in Phase 1 clinical trials: JANUX007, a PSMA-targeted TRACTr for metastatic castration-resistant prostate cancer, and JANUX008, an EGFR-targeted candidate for solid tumors including colorectal, head and neck, lung, renal, and pancreatic cancers.
The company maintains a strategic research collaboration with Merck Sharp & Dohme to advance TRACTr product candidates, providing a partnership component to its development pipeline. Janux operates with a lean structure of 109 full-time employees and is headquartered in San Diego, California. The company was incorporated in Delaware in 2017 and trades on Nasdaq. As a pre-revenue clinical-stage entity, Janux's business model depends on advancing its clinical candidates through regulatory milestones and securing capital through financing activities and partnership arrangements.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-1.83 | $-1.83 | -43.0% | |
| 2024 | $-1.28 | $-1.28 | +3.0% | |
| 2023 | $-1.32 | $-1.32 | +13.2% | |
| 2022 | $-1.52 | $-1.52 | — | |
| 2021 | — | — | — |